From Financial Modeling Prep: 2024-10-30 09:23:31

In summary, Exelixis, Inc. (NASDAQ:EXEL) received a price target of $38 from Truist Financial, suggesting a potential upside of 32.27%. The Q3 2024 earnings call showcased the company’s financial results and strategic focus on Cabometyx, its flagship cancer treatment product. With a market capitalization of $8.2 billion, Exelixis remains a key player in the biotech industry, attracting investor attention and market volatility.



Read more at Financial Modeling Prep:: Exelixis, Inc. (NASDAQ:EXEL) Overview and Financial Outlook